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Introduction: The EML4–anaplastic lymphoma kinase (ALK) trans-
location is a recognized oncogenic driver in non-small cell lung
cancer. We investigated immunohistochemistry (IHC) screening
with fluorescence in situ hybridization (FISH) confirmation for ALK
detection and estimated the prevalence of ALK positivity in our
patient cohort of never-smokers, together with differences in clinical
outcomes and prognostic factors for patients with ALK-positive and
ALK-negative tumors.
Methods: We designed a three-phase study (training, validation, and
testing) in 300 never-smokers with lung adenocarcinoma from the
observational Mayo Clinic Lung Cancer Cohort. Tumor samples were
tested using IHC and FISH, and concordance between the methods was
assessed. Clinical outcomes were assessed via 5-year progression- or
recurrence-free survival from diagnosis. Prognostic factors for ALK-
positive tumors and metastases were also investigated.
Results: ALK-positive patients were significantly (p  0.05)
younger and had higher grade tumors than ALK-negative patients.
ALK positivity was 12.2% by IHC and confirmed at 8.2% of tumors
by FISH, with complete concordance between IHC 3/0 and
FISH/ assessments, respectively. Five-year risk of progression
or recurrence was doubled for patients with ALK-positive compared
with ALK-negative tumors; ALK-positive tumors also appeared to be
associated with a higher risk of brain and liver metastases.
Conclusions: Our findings suggest that ALK positivity is associated
with a significantly poor outcome in nonsmoking-related adenocar-
cinoma and that ALK-positive tumors may be associated with an
increased risk of brain and liver metastases compared with ALK-
negative disease. Consequently, an unmet medical need exists in
ALK-positive lung cancer patients, and effective ALK-specific ther-
apies are needed.
Key Words: EML4–anaplastic lymphoma kinase, Non-small cell
lung cancer, Immunohistochemistry, Fluorescence in situ hybridiza-
tion, Progression- and recurrence-free survival.
(J Thorac Oncol. 2012;7: 90–97)
The echinoderm microtubule-associated protein-like 4(EML4)–anaplastic lymphoma kinase (ALK) translocation
was discovered in non-small cell lung cancer (NSCLC) in
2007.1 The EML4–ALK translocation can result in constitu-
tive ALK kinase activity and represents an oncogenic addic-
tion pathway in lung cancer.2 Other ALK fusion variants have
also been reported, with uncertain oncokinase functions in
NSCLC.3–5 Several studies have shown ALK gene rearrange-
ment (ALK positivity) to correlate with never or light/former
smoking status, younger age, adenocarcinoma histology, and
to rarely coincide with EGFR or KRAS mutation.6–11 Retro-
spective studies have reported prevalence estimates for ALK
positivity ranging from 1.67 to 13%,8 the variability resulting
from factors including the methodology used to detect ALK
gene rearrangement (e.g., polymerase chain reaction with
limited probe sets) and patient or tissue selection criteria.
Therefore, several questions remain to be answered, includ-
ing the true prevalence of ALK positivity in unselected patient
populations and whether prevalence varies by disease stage,
geography, or ethnicity. Moreover, the natural history and
clinical outcome of ALK-positive versus ALK-negative pa-
tients needs to be fully defined.
In an effort to find a cost-effective method for selecting
ALK-positive NSCLC patients who may benefit from ALK
inhibitor therapies, we studied the role of scored immunohis-
tochemistry (IHC) as a screening test. Given the high con-
cordance between IHC score and ALK status by fluorescence
in situ hybridization (FISH), we proposed an algorithm for
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FISH confirmation.12 In this study, we have further validated
and tested the algorithm and performed a controlled compar-
ison of clinical outcomes for ALK-positive versus ALK-
negative adenocarcinoma patients. Our four specific objec-
tives were to (1) assess whether IHC can be a practical tool
for ALK screening in adenocarcinoma with a confirmatory
FISH test; (2) estimate the prevalence of ALK positivity in
our enriched study cohort by either or both IHC and FISH
tests; (3) describe clinical characteristics of cases by IHC
score, FISH status, and combined IHC and FISH results; and
(4) most importantly, evaluate clinical outcomes of ALK-
positive versus ALK-negative cases, while controlling for
clinically important prognostic factors, in a naturally fol-
lowed observational patient cohort.
MATERIALS AND METHODS
Study Design, Sampling, and Data Collection
To evaluate the ALK test concordance and estimate
ALK positivity prevalence, we designed a three-phase study
in an ALK-positive-enriched patient population: approxi-
mately 100 patients were included in each phase as a training
(n  100), validation (n  99), and testing set (n  101),
respectively (Supplemental Figure 1).
All patients were never-smokers, defined as having
smoked zero to 99 cigarettes during their lifetime, and were
selected from the Mayo Clinic Lung Cancer Cohort, an
observational follow-up study.13,14 The sample enrichment
strategy included only never-smokers with adenocarcinoma
diagnosed between 1997 and 2008 (none treated with crizo-
tinib), with surgically resected samples, preserved as forma-
lin-fixed paraffin-embedded tissue. These samples were from
surgical treatments (i.e., lobectomy, pneumonectomy, and
sleeve resection) or biopsies (i.e., wedge, pleural, and/or
thoracotomy-based). In total, 300 cases were eligible for
inclusion in the analyses. All eligible cases had banked tissue
samples from surgical resections consisting of wedge resec-
tion or more extensive surgeries; available slides from each
case were reviewed by two pathologists (E.S.Y. and M.C.A.)
to verify the diagnosis and to select the representative block
containing the most architecturally intact tumor cells.
Follow-up is accomplished through detailed medical
record review and patient questionnaires at within 6 months
postdiagnosis and then annually. For deceased patients, the
follow-up questionnaire is sent to the next-of-kin. Additional
details regarding patient identification and follow-up have
been described previously.15,16 Information abstracted from
the medical record for each patient included age, gender,
race, smoking status, history of tobacco exposure, other
medical conditions, symptoms at presentation, and Eastern
Cooperative Oncology Group performance status. For the
initial diagnosis of primary NSCLC, date of diagnosis, clin-
ical stage, histopathological type and grade of tumor, type of
surgical resection, and the use of adjuvant therapy were
recorded. The evidence of progression and/or recurrent dis-
ease was abstracted from Mayo Clinic medical records or
other reliable sources. Additional sources of data collection
included lung cancer follow-up questionnaires, tumor registry
questionnaires routinely sent to the patient from Mayo Clinic,
and correspondence letters or copied medical records re-
ceived from outside clinicians. When the presence or absence
of progression and/or recurrent disease was documented at
another institution, data were included only when the infor-
mation was specific and considered reliable.15 To standardize
the quality of follow-up information across all patients, fol-
low-up information completed as of December 31, 2010, was
included in the analysis.
IHC and FISH for ALK Rearrangement
Immunohistochemistry
IHC using ALK1 monoclonal antibody (Dako, Carpin-
teria, CA) was performed as described previously by Yi et
al.12 An IHC score was assigned to each case according to the
following criteria with at least 10% of tumor cells showing
the designated staining pattern: 3, intense, granular cy-
toplasmic staining; 2, moderate, smooth cytoplasmic
staining; 1, faint cytoplasmic staining; and 0, no stain-
ing. IHC scoring was performed without the knowledge of
FISH results.
FISH for ALK Rearrangement
Interphase molecular cytogenetic studies using a com-
mercially available ALK probe (Vysis, Des Plaines, IL) were
performed as described previously by Yi et al.12 FISH for
ALK locus rearrangement was considered positive if 15% or
more of at least 100 cells counted showed splitting of the
florescent probes flanking the ALK locus. All FISH interpre-
tation was performed without the knowledge of IHC results
for ALK.
Study End Points
Survival was assessed as 5-year progression-free or
recurrence-free survival (PFS/RFS) from diagnosis (events
occurring after 5 years were censored and cases died before
recurrence/progression counted as events). To control for
confounding effects of known predictors for lung cancer
progression or recurrence, the following variables were
matched or adjusted for age at diagnosis, sex, lung cancer
stage (I, II, III, and IV), and mode of treatment (surgery only,
surgery and chemo/radiation, other/none/ unknown).
Statistical Analyses
Descriptive statistics were summarized and compared
for a number of factors, including age at diagnosis, sex,
ethnicity (U.S. white versus other), grade of tumor differen-
tiation (well differentiated, moderately differentiated, poorly
or undifferentiated), stage, and treatment modality. Prepro-
gression treatment included all treatment received before
primary progression, recurrence, or development of second
primary tumors. Both univariate and multivariate survival
analyses were conducted by ALK status using IHC, FISH, and
both combined IHC and FISH test scores comparing patients
with ALK-positive tumors with patients with ALK-negative
tumors. Five levels of analyses were performed: (1) compar-
ison of patients’ characteristics by ALK status using Kruskal–
Wallis tests (continuous variables) and 2 tests or Fisher’s
exact tests (categorical variables); (2) IHC and FISH tests
concordance of ALK status analyzed by 2 tests for homoge-
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neity; (3) the prevalence of ALK-positive cases estimated by
IHC test only, by FISH test only, and by both tests; (4)
PFS/RFS by ALK status using adjusted (unmatched) and
matched (a nested case–case) Cox proportional hazard mod-
els in which the hazard ratio or relative risk of the end point
was estimated; and (5) comparison of detailed events of
progression and recurrence between ALK-positive and ALK-
negative cases. The “full model” used all covariates (age, sex,
stage, and preprogression treatment) and the “select model”
employed a stepwise model selection procedure to pick the
significant covariates. A Cox proportional hazards model was
used to estimate the partial effects of stage; specifically for
each individual, two survival curves were estimated for each
value of stage, with individual covariates remaining fixed.
The adjusted survival curves are then calculated as the with-
in-stage mean estimated survival of all study subjects.
RESULTS
Descriptive Analysis
Patient characteristics by FISH status, IHC score, and
both IHC score and FISH status combined are shown in Table
1. In total, 300 patients had IHC scores, 216 had FISH results,
and 300 had either of the two tests. All cases with IHC1,
2, or 3 have been tested for FISH, and the 84 cases
without FISH were IHC score 0. Across the three groups, a
statistically significant difference between ALK-positive and
ALK-negative cases was observed for age at diagnosis, tumor
cell differentiation (grade), and treatment modality. In addi-
tion, stage was significantly different between FISH-positive
and FISH-negative groups. Patients with ALK-positive tu-
mors were younger and had more aggressive histologic grade
TABLE 1. Patient Characteristics by IHC Score, FISH Status, and IHC Score/FISH Status Combined


























Age at diagnosis, yr
Median 59.0 56.5 70.0 70.0 62.5 70.0 58.0 70.0
Range 36.0–77.0 40.0–84.0 41.0–91.0 17.0–89.0 36.0–77.0 32.0–91.0 36.0–84.0 17.0–91.0
Gender, n (%)
Female 11 (61.1) 13 (92.9) 46 (70.8) 155 (76.4) 14 (63.6) 147 (75.8) 26 (76.5) 199 (74.8)
Male 7 (38.9) 1 (7.1) 19 (29.2) 48 (23.6) 8 (36.4) 47 (24.2) 8 (23.5) 67 (25.2)
Race, n (%)
Caucasian 18 (100.0) 11 (78.6) 58 (89.2) 176 (86.7) 21 (95.5) 172 (88.7) 31 (91.2) 232 (87.2)
Other 0 (0.0) 3 (21.4) 7 (10.8) 27 (13.3) 1 (4.5) 22 (11.3) 3 (8.8) 34 (12.8)
Grade of differentiation, n (%)
Well differentiated 4 (22.2) 5 (35.7) 27 (41.5) 125 (61.6) 5 (22.7) 105 (54.1) 10 (29.4) 151 (56.8)
Moderately differentiated 10 (55.6) 8 (57.1) 31 (47.7) 62 (30.5) 12 (54.5) 75 (38.7) 19 (55.9) 92 (34.6)
Poorly/undifferentiated 4 (22.2) 1 (7.1) 7 (10.8) 16 (7.9) 5 (22.7) 14 (7.2) 5 (14.7) 23 (8.6)
Stage, n (%)
I 6 (33.3) 7 (50.0) 32 (49.2) 130 (64.0) 7 (31.8) 122 (62.9) 14 (41.2) 161 (60.5)
II 2 (11.1) 2 (14.3) 2 (3.1) 10 (4.9) 2 (9.1) 7 (3.6) 4 (11.8) 12 (4.5)
III 5 (27.8) 4 (28.6) 16 (24.6) 37 (18.2) 7 (31.8) 37 (19.1) 10 (29.4) 52 (19.5)
IV 5 (27.8) 1 (7.1) 15 (23.1) 26 (12.8) 6 (27.3) 28 (14.4) 6 (17.6) 41 (15.4)
Treatment modality, n (%)
Only surgery 5 (27.8) 9 (64.3) 37 (56.9) 136 (67.0) 7 (31.8) 122 (62.9) 15 (44.1) 172 (64.7)
Surgery and chemo/radiation 9 (50.0) 5 (35.7) 15 (23.1) 44 (21.7) 11 (50.0) 49 (253) 15 (44.1) 58 (21.8)
Other/none/unknown 4 (22.2) 0 (0.0) 13 (20.0) 23 (11.3) 4 (18.2) 23 (11.9) 4 (11.8) 36 (13.5)
Preprogression treatment, n (%)
Only surgery 8 (44.4) 11 (78.6) 40 (61.5) 147 (72.4) 10 (45.4) 137 (70.6) 20 (58.8) 186 (69.9)
Surgery and chemo/radiation 5 (27.8) 3 (21.4) 12 (18.5) 32 (15.8) 7 (31.8) 34 (17.5) 9 (26.5) 43 (16.2)
Other/none/unknown 5 (27.8) 0 (0.0) 13 (20.0) 24 (11.8) 5 (22.7) 23 (11.9) 5 (14.7) 37 (13.9)
Median PFS/RFS 2.05 3.33 3.89 4.40 2.18 4.48 2.66 4.27
Shaded variables are statistically different (p  0.05) among the comparison groups.
Not all patients had surgically resected lung cancer. Not all resected tissue came from curative surgery. Some tissue samples were from wedge, pleural, or thoracotomy-based
biopsies.
“Unknown” treatments were for patients who received treatment outside our institution and the data are still being verified. “Other” treatments included TAC of pleura and
removal of solitary brain metastasis.
FISH, fluorescence in-situ hybridization; IHC, immunohistochemistry; PFS/RFS, progression- or recurrence-free survival.
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and more advanced disease stage than those with ALK-
negative tumors.
Concordance Analysis
There were 225 samples tested by both assays from 221
distinct patients (four patients each had two samples tested).
Concordance rates between IHC scores and FISH status are
presented in Supplemental Table 1. Complete concordance
(100%) was observed between IHC3 scores and FISH-
positive status and between IHC0 scores and FISH-negative
status. Relatively high concordance was seen between
IHC1 scores and FISH-negative status (96.9% of IHC1
was FISH negative); while reasonable concordance was noted
between IHC2 scores and FISH-negative status (85.7% of
IHC2 was FISH negative).
ALK Positivity Prevalence Estimation
The prevalence of ALK tumors was estimated using five
methods (Supplemental Table 2): (1) using IHC as a screen-
ing test, the prevalence of ALK positivity was 10.7% for
IHC3/2, 6.0% for IHC3, and 4.7% for IHC2; (2) by
FISH, the prevalence was 8.2%; (3) using IHC as a screening
test and FISH as a confirmatory “gold standard” test, the
prevalence was 8.2% for FISH-positive or IHC3; (4) the
prevalence was 12.2% for FISH-positive or IHC3 or
IHC2 in the training and validation sets; and (5) counting
all FISH-positive and all IHC3/2 cases in the entire
prevalence cohort, the prevalence was 11.3%.
Survival Analysis
PFS/RFS was evaluated using two comparative analy-
ses. In the unmatched analysis, three models (unadjusted, full,
and select) considered samples as ALK-positive using three
alternative definitions: IHC3, FISH, or both FISH and
IHC3. The select model adjusted for tumor stage only. As
shown in Table 2, results were consistent across all models:
the risk of experiencing lung cancer progression or recurrence
within 5 years after diagnosis was greater than two-fold in
ALK-positive cases compared with ALK-negative cases.
Stage-adjusted survival curves for the three ALK-positive
definitions are shown in Figure 1.
The matched analysis used three similar scenarios
based on IHC/FISH tests and on the number of matches of
ALK-negative cases to each ALK-positive case. Results were
consistent, showing a greater than two-fold increased risk of
progression and/or recurrence in patients with ALK-positive
tumors (Supplemental Table 3).
Detailed Comparison of Progression and
Recurrence Events between ALK-Positive and
ALK-Negative Cases
Location of metastases at diagnosis by ALK status was
available for 47 advanced-stage (local, regional, and remote
metastasis) lung cancer cases and is presented in Supplemen-
tal Table 4 as descriptive information. The six patients with
ALK-positive tumors appeared to have a greater frequency of
chest cavity, brain, bone, and liver metastases than ALK-
negative patients. However, no formal statistical test was
performed due to small sample size.
TABLE 2. Analysis of 5-yr PFS/RFS by Cox Proportional
Hazards Models
HR (95% CI) p
PFS/RFS, IHC3 (n  18) vs. IHC0/1
(n  264)
Unadjusted 3.33 (1.79–6.17) 0.0001
Full modela 2.14 (1.12–4.07) 0.0210
Age at diagnosis (per 1 yr) 0.99 (0.97–1.02) 0.5658
Sex (males) 1.47 (0.89–2.43) 0.1345
Stage (vs. I)
II 1.40 (0.41–4.78) 0.5931
III 3.74 (1.97–7.09) .0001
IV 3.19 (1.48–6.82) 0.0029
Treatment (vs. only surgery)
Surgery and chemotherapy or radiation 1.68 (0.89–3.18) 0.1101
Other/none/unknown 2.32 (1.09–4.91) 0.0287
Select modelb 2.37 (1.27–4.46) 0.0071
Stage (vs. I)
II 1.40 (0.42–4.46) 0.5862
III 5.26 (3.07–9.03) .0001
IV 5.04 (2.71–9.36) .0001
PFS/RFS, FISH (n  22) vs. FISH
(n  191)
Unadjusted 3.10 (1.75–5.52) 0.0001
Full modela 1.95 (1.07–3.58) 0.0303
Age at diagnosis (per 1 yr) 1.00 (0.98–1.02) 0.7575
Sex (males) 1.36 (0.80–2.34) 0.2588
Stage (vs. I)
II 0.99 (0.23–4.27) 0.9872
III 3.49 (1.78–6.83) 0.0003
IV 3.46 (1.43–8.36) 0.0058
Treatment (vs. only surgery)
Surgery and chemotherapy or radiation 1.40 (0.72–2.71) 0.3183
Other/none/unknown 2.24 (0.91–5.53) 0.0800
Select modelb 2.11 (1.17–3.82) 0.0134
Stage (vs. I)
II 1.02 (0.24–4.36) 0.9741
III 4.48 (2.55–7.87) .0001
IV 5.59 (2.86–10.93) .0001
PFS/RFS, FISH/IHC3 (n  22) vs.
FISH/IHC0/1 (n  274)
Unadjusted 3.37 (1.92–5.90) 0.0001
Full modela 2.00 (1.11–3.61) 0.0208
Age at diagnosis (per 1 yr) 0.99 (0.97–1.01) 0.3387
Sex (males) 1.34 (0.82–2.19) 0.2491
Stage (vs. I)
II 1.23 (0.37–4.14) 0.7347
III 3.78 (2.04–7.00) .0001
IV 3.45 (1.65–7.19) 0.0010
Treatment (vs. only surgery)
Surgery and chemotherapy or radiation 1.51 (0.82–2.79) 0.1881
Other/none/unknown 2.15 (1.03–4.46) 0.0408
Select modelb 2.31 (1.31–4.10) 0.0040
Stage (vs. I)
II 1.22 (0.37–4.04) 0.7421
III 5.03 (2.99–8.46) .0001
IV 5.24 (2.88–9.53) .0001
a Adjusted for age at diagnosis, sex, stage, and treatment preprogression.
b Adjusted for stage.
FISH, fluorescence in-situ hybridization; IHC, immunohistochemistry; PFS/RFS,
progression- or recurrence-free survival; HR, hazard ratio; CI, confidence interval.
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Table 3 provides descriptions of the location and num-
ber of events in the survival cohort (n  299) by four ALK
status subgroups. With the exception of adrenal glands, the
ALK-positive group reported higher percentages of events for
all individual locations than the combined ALK-negative
groups, whereas the 12 IHC2 cases (considered as ALK
negative unless also FISH-positive) had an event occurrence
pattern which fell between patterns seen for the ALK-positive
and the two other ALK-negative subgroups (IHC0, IHC1).
More detailed event data by specific ALK test results are
provided in Supplemental Tables 5 and 6. Specified adjusted
Cox model results indicated that a significantly higher risk of
extrathoracic events (brain and liver) was observed in patients
harboring ALK-positive tumors versus ALK-negative tumors
(Table 4).
DISCUSSION
This study confirms earlier results by our group that
IHC scores 3 and 0 were 100% concordant with FISH-
positive and FISH-negative status, respectively, whereas IHC
scores 1 and 2 may require further confirmatory testing.12 In
addition, we report the first ALK-positive prevalence estimate
in an enriched sample of never-smokers with adenocarci-
noma. Prevalence rates ranged from 6.0% (by IHC3) to
12.2% (FISH-positive/IHC3/2). This study also suggests,
through controlled and matched analyses, a less favorable
clinical outcome for ALK-positive compared with ALK-neg-
ative cases. Of note, we found that the risk of lung cancer
progression or recurrence in the 5 years postdiagnosis dou-
bled in ALK-positive cases compared with ALK-negative
cases (as defined by IHC, FISH, or combined IHC and FISH).
Furthermore, despite the small sample size of ALK-positive
patients and the small number of events, patients with ALK-
positive tumors appeared to have a higher risk of developing
tumor progression and/or recurrence in the brain and liver
than patients with ALK-negative tumors.
We initially hypothesized that a high proportion of
IHC2 patients would also be FISH-positive. However,
IHC–FISH concordance in this group was low, with only
14.3% of the 14 IHC2 cases being FISH-positive. There-
fore, we recommend confirmatory testing with FISH for any
case showing IHC2. As the patient and clinical character-
istics of the IHC2 group appeared intermediate between
those for the IHC3 and IHC1 groups (see Tables 1 and 3
and Supplemental Table 5), we grouped IHC3 and IHC2
patients together as an exploratory scenario for IHC–ALK
positivity. Patients with IHC1 had a very low rate of FISH
positivity, with only 3.1% of IHC1 cases showing ALK
rearrangement. For practical purposes, IHC1 cases can be
considered ALK negative. However, in an attempt to capture
FIGURE 1. A, Stage-adjusted progression- or recurrence-free survival (PFS/RFS) curves for immunohistochemistry (IHC) 3
(positive) versus IHC0/1 (negative) cases. B, Stage-adjusted PFS/RFS survival curves for fluorescence in situ hybridization
(FISH)-positive and FISH-negative cases. C, Stage-adjusted PFS/RFS survival curves for FISH/IHC3 (positive) and FISH-nega-
tive/IHC0/1 (negative) cases (see Select model data in Table 2).
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all patients with ALK rearrangement, targeted FISH testing
could be considered for some adenocarcinoma patients with
IHC1, especially if they have other characteristics associ-
ated with ALK positivity (never-smoker status, young age,
TABLE 3. Number of Lung Cancer Recurrences and/or
Progressions by Location and ALK Statusa
ALK
(n  22)b







No. recurrence or progression,
n (%)
6 (30.0) 7 (58.3) 46 (73.0) 153 (76.1)
No. in intrathoracic
regionc, n (%)
1 4 (200) 1 (8.3) 8 (12.7) 17 (8.5)
2 4 (20.0) 3 (25.0) 6 (9.5) 21 (10.4)
No. in same lung, n (%)
1 4 (20.0) 3 (25.0) 9 (14.3) 26 (129)
2 2 (10.0) 0 (0.0) 4 (6.4) 8 (4.0)
No. in other lung, n (%)
1 1 (5.0) 2 (16.7) 3 (4.8) 14 (70)
2 2 (10.0) 1 (8.3) 3 (4.8) 7 (3.5)
No. in chest cavityd,
n (%)
1 3 (15.0) 2 (16.7) 2 (3.2) 6 (3.0)
2 0 (0.0) 0 (0.0) 0 (0.0) 3 (1.5)
No. in extrathoracic
regione, n (%)
1 6 (30.0) 2 (16.7) 6 (9.5) 16 (8.0)
2 3 (15.0) 1 (8.3) 3 (4.8) 9 (4.5)
No. in brain, n (%)
1 4 (20.0) 3 (25.0) 3 (4.7) 9 (4.5)
2 1 (5.0) 0 (0.0) 0 (0.0) 1 (0.5)
No. in bonesf, n (%)
1 2 (10.0) 1 (8.3) 3 (4.8) 8 (4.0)
2 0 (0.0) 0 (0.0) 1 (1.6) 4 (2.0)
No. in liver, n (%)
1 2 (10.0) 0 (0.0) 0 (0.0) 3 (1.5)
2 0 (0.0) 0 (0.0) 1 (1.6) 0 (0.0)
No. in kidneys, n (%)
1 1 (5.0) 0 (0.0) 0 (0.0) 0 (0.0)
No. in adrenal
glands, n (%)
1 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.0)
No. in other sitesg, n (%)
1 3 (15.0) 0 (0.0) 1 (1.6) 6 (3.0)
2 0 (0.0) 0 (0.0) 1 (1.6) 2 (1.0)
n  299 cases in the survival cohort.
a Anaplastic lymphoma kinase (ALK) is fluorescence in-situ hybridization
(FISH) and/or immunohistochemistry (IHC)3, and ALK is FISH and/or
IHC0/1 (included in ALK if FISH and IHC1).
b Two ALK cases and one IHC0 case have unknown locations for their recur-
rences and/or progressions; reported percentages are out of n  20 ALK cases and
n  201 IHC0 cases.
c Intrathoracic—includes same lung, other lung, and chest cavity.
d Chest cavity—includes mediastinum, pleural effusion, pleural nodes, and
pericardium.
e Extrathoracic—includes brain, bones (including ribs), liver, kidneys, adrenal
glands, and other sites.
f Bones—includes all bones of the body, including ribs.
g Other sites—includes all areas of the body not otherwise specified.
TABLE 4. Five-Year Time-to-Recurrence and/or Progression





Unadjusted 1.98 (0.90–4.35) 0.09
Full model 0.71 (0.30–1.69) 0.44
Select modela 0.76 (0.33–1.76) 0.53
Same lung
Unadjusted 1.57 (0.62–3.96) 0.34
Full model 0.74 (0.24–2.32) 0.61
Select modelb 1.16 (0.45–2.99) 0.76
Other lung
Unadjusted 1.57 (0.48–5.17) 0.46
Full model 1.20 (0.20–7.16) 0.85
Select modelc 2.46 (0.72–8.32) 0.15
Chest cavity
Unadjusted 3.56 (1.00–12.65) 0.05
Full model 9.56 (1.54–59.40) 0.02
Select modeld 4.06 (0.98–16.90) 0.05
Extrathoracic
Unadjusted 3.80 (1.82–7.92) 0.001
Full model 2.53 (1.11–5.76) 0.03
Select modele 2.44 (1.12–5.36) 0.03
Brain
Unadjusted 4.75 (1.74–12.98) 0.002
Full model 4.46 (1.37–14.51) 0.01
Select modelf 4.55 (1.50–13.78) 0.007
Liver
Unadjusted 6.90 (1.26–37.69) 0.03
Full model Cannot be calculated —
Select modelg 8.22 (1.06–63.51) 0.04
Bones, kidneys, or adrenal glands Samples too small —
Other sites
Unadjusted 4.92 (1.33–18.24) 0.02
Full model 3.25 (0.30–35.11) 0.33
Select modelh 1.14 (0.16–8.12) 0.89
Intrathoracic—includes same lung, other lung, and chest cavity.
Chest cavity—includes mediastinum, pleural effusion, pleural nodes, and
pericardium.
Extrathoracic—includes brain, bones, liver, kidneys, adrenal glands, and other sites.
Other sites—includes all areas of the body not otherwise specified.
Treatment includes all treatments before the first event of second primary, recur-
rence, or progression.
Full model  anaplastic lymphoma kinase (ALK) status, age at diagnosis, sex,
stage, treatment, and remaining regions (e.g., same lung event is adjusted for other lung,
chest cavity, brain, bones, liver, kidneys, adrenal glands, other sites, etc.).
Select model ALK status and a stepwise model selection for the above covariates.
Event with unknown location—all location variables were set to “no” to preserve
sample size.
Model information: Time  time to first recurrence or progression; Event  event
location (e.g., intrathoracic, same lung, brain, etc.) at any time. For example, the first
recurrence could be intrathoracic, but if they had an extrathoracic recurrence 2 months
later, extrathoracic would be an event and the time for the extrathoracic event would be
the same as the intrathoracic event. Extrathoracic event would be a covariate in the
intrathoracic model and vice versa.
a Adjusted for stage and extrathoracic.
b Adjusted for treatment, other lung, chest cavity, and other sites.
c Adjusted for same lung.
d Adjusted for same lung and liver.
e Adjusted for sex, stage, treatment, and intrathoracic.
f Adjusted for stage, same lung, and bones.
g Adjusted for treatment, other lung, and bones.
h Adjusted for sex, stage, treatment, same lung, and kidneys.
Journal of Thoracic Oncology • Volume 7, Number 1, January 2012 Worse Disease-Free Survival in Never-Smokers
Copyright © 2011 by the International Association for the Study of Lung Cancer 95
signet ring morphology, negativity for EGFR and KRAS
mutations). The biological basis for the observed discordance
in cases showing IHC2 and FISH negativity is under
investigation by our group and may be due to nonspecific
IHC staining, a unique ALK fusion variant or mutation not
identified by one or both of the FISH probes used or could be
the result of normal ALK protein aberrantly expressed by
some other mechanisms. These cases could represent a “tran-
sitional” phase of an oncogenic process, and it may be
important to determine whether patients with an IHC score of
2 may also benefit from ALK-targeted therapy.
Although several studies have shown that ALK-positive
cases were more likely to have never or light/former smoking
status and adenocarcinoma histology,6,8,10 ALK-positive cases
have been reported in current smokers1,2,17,18 and in nonade-
nocarcinoma histology.9,17,19 Furthermore, ALK positivity has
been reported along with the EGFR exon 1910 and exon 20
mutations,20 despite ALK positivity and EGFR mutations
being mutually exclusive in all other studies to date. There-
fore, other evaluation procedures should be explored to max-
imize the opportunity for these “exceptional” cases to also
benefit from ALK-targeted therapy.
Recent studies, attempting to elucidate the natural his-
tory of ALK-positive NSCLC in terms of response to standard
therapies, have demonstrated no statistically significant dif-
ference in platinum-based chemotherapy response rates in
ALK-positive compared with ALK-negative patients.2,8 Al-
though not statistically significantly different, response rates
were numerically smaller in ALK-positive patients. Shaw et
al.8 reported a chemotherapy response rate for ALK-positive
patients (n 12) of 25% versus 50% for EGFR-mutated (n
8) and 35% for ALK/EGFR wild-type patients (n  34),
suggestive of a trend toward a poorer response to chemother-
apy in the ALK-positive patients; however, this analysis did
not adjust for between-group differences in age and smoking
history. Likewise, Koh et al.2 reported a first-line response
rate to platinum-based chemotherapy of 18.8% in ALK-
positive versus 34.4% in ALK-negative patients (p  0.088).
Importantly, these two studies found that patients with ALK-
positive NSCLC did not respond well to EGFR tyrosine
kinase inhibitors, an association that was statistically signif-
icant.2,8 More recently, Camidge et al.21 and Lee et al.22 have
presented data suggesting that ALK is predictive for favorable
outcome with pemetrexed-based therapy. Shaw et al.23 dem-
onstrated significantly prolonged overall survival in ALK-
positive NSCLC patients treated within a clinical trial of the
experimental ALK inhibitor, crizotinib, when indirectly com-
pared with nontrial patients with ALK-positive NSCLC who
were treated with standard therapy. Taken together, these
studies show that patients with ALK-positive tumors do not
have a more favorable clinical outcome with existing
standard therapies, perhaps with the exception of pem-
etrexed-based therapy. ALK-specific inhibitors may prove
to prolong overall survival, and ALK positivity is a nega-
tive predictive marker for EGFR tyrosine kinase inhibitor
treatment outcomes.
Our current study adds further evidence that ALK-
positive NSCLC patients do not have a more favorable
prognostic course of disease, as is the case in ALK-rearranged
anaplastic large cell lymphoma.24,25 Rather, our data clearly
demonstrate a less favorable prognosis, as measured by
5-year PFS/RFS. These findings may be due to complete
clinical data ascertainment and the thorough consideration of
potential confounding variables in all analyses. On the other
hand, as with other retrospective studies of this rare gene
rearrangement, the small sample size, the observational as-
sessment of progression or recurrence, unknown EGFR status
in some cases, and the use of a broad category of treatment
modality may have affected our estimates. Our ongoing
analyses will assess treatment and stage-specific outcomes
with respect to known EGFR status as well as the correlation
of signet ring cell morphology, ALK status, and clinical
outcomes.
Because we have included an all-inclusive patient co-
hort of never-smokers with testable tissue sample, propor-
tionally we have had a cohort with more early-stage or
surgically treated patients, as opposed to most other ALK-
related studies focusing on late-stage patients. As a conse-
quence, much longer follow-up time is required to obtain
mature data for overall survival analysis. In the near future,
we will achieve a complete view of treatment modalities and
their effects on treatment outcomes including overall survival
stratified by ALK status.
In conclusion, our results suggest that ALK-specific
therapies are needed for patients with ALK-positive tumors
due to significant worse 5-year PFS/RFS survival. In addi-
tion, if our data regarding a greater risk of brain or liver
metastases are corroborated with more robust data, it will be
even clearer that there is, indeed, an unmet and urgent
medical need in the ALK-positive NSCLC patient population.
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